High dose-rate tandem and ovoid brachytherapy in cervical cancer: dosimetric predictors of adverse events

被引:18
|
作者
Romano, Kara D. [1 ]
Hill, Colin [1 ]
Trifiletti, Daniel M. [1 ]
Peach, M. Sean [1 ]
Horton, Bethany J. [2 ]
Shah, Neil [1 ]
Campbell, Dylan [1 ]
Libby, Bruce [1 ]
Showalter, Timothy N. [1 ]
机构
[1] Univ Virginia, Dept Radiat Oncol, Sch Med, 1240 Lee St,Box 800383, Charlottesville, VA 22908 USA
[2] Univ Virginia, Sch Med, Div Translat Res & Appl Stat, Dept Publ Hlth Sci, Charlottesville, VA 22908 USA
关键词
IMAGE-GUIDED BRACHYTHERAPY; SOCIETY CONSENSUS GUIDELINES; LOCALLY ADVANCED-CARCINOMA; AMERICAN BRACHYTHERAPY; ADAPTIVE BRACHYTHERAPY; WORKING GROUP; VOLUME; DELINEATION; PARAMETERS; SURVIVAL;
D O I
10.1186/s13014-018-1074-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Brachytherapy (BT) is a vital component of the curative treatment of locally advanced cervical cancer. The American Brachytherapy Society has published guidelines for high dose rate (HDR) BT with recommended dose limits. However, recent reports suggest lower doses may be needed to avoid toxicity. The purpose of this study is to investigate incidence and predictive factors influencing gastrointestinal (GI) and genitourinary (GU) toxicity following HDR intracavitary brachytherapy for locally advanced cervical cancer. Methods: We retrospectively evaluated a cohort of patients with locally advanced cervical cancer who received CT-based HDR BT. Cumulative doses were calculated using the linear-quadratic model. Statistical analyses were used to investigate clinical and dosimetric predictors of GI and GU toxicity following HDR brachytherapy according to CTCAE v4.0 grading criteria. Results: Fifty-six women with FIGO IB1 - IVA cervical cancer were included. The overall rate of any GU adverse event (Grade 1+) was 23.3% (n = 13) and severe adverse events (Grade 3+) was 7.1% (n = 4). Of those, the bladder equivalent dose in 2- Gray (Gy) fractions (EQD(2)) D-2cc was >= 80 for three of the four patients. The overall rate of any GI adverse event was 26.8% (n = 15) and the rate of severe adverse events was 14.3% (n = 8). Of those, six of the eight patients had a rectal EQD(2) D-2cc >= 65 Gy and seven patients had a sigmoid D-2cc >= 65 Gy. Amongst clinically meaningful factors for development of adverse events (i.e. diabetes, smoking status, ovoid size, and treatment duration), there were no statistically significant prognostic factors identified. Conclusions: Severe adverse events are observed even with adherence to current ABS guidelines. In the era of recent multi-institutional study results, our data also supports more stringent dosimetric goals. We suggest cumulative D2cc dose limits of less than 80 Gy for the bladder and less than 65 Gy for the rectum and sigmoid.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Indian Brachytherapy Society Guidelines for radiotherapeutic management of cervical cancer with special emphasis on high-dose-rate brachytherapy
    Mahantshetty, Umesh
    Gudi, Shivakumar
    Singh, Roshni
    Sasidharan, Ajay
    Sastri, Supriya
    Gurram, Lavanya
    Sharma, Dayanand
    Ganeshrajah, Selvaluxmy
    Janaki, M. G.
    Badakh, Dinesh
    Basu, Abhishek
    James, Francis
    Swamidas, Jamema, V
    Kuppuswamy, Thayalan
    Bhalavat, Rajendra
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2019, 11 (04) : 293 - 306
  • [22] Three-dimensional dosimetric considerations from different point A definitions in cervical cancer low-dose-rate brachytherapy
    Zhang, Miao
    Chen, Ting
    Kim, Leonard H.
    Nelson, Carl
    Gabel, Molly
    Narra, Venkat
    Haffty, Bruce
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2013, 5 (04) : 222 - 226
  • [23] Combined Interstitial and Intracavitary High-Dose Rate Brachytherapy of Cervical Cancer
    Itami, Jun
    Murakami, Naoya
    Watanabe, Miho
    Sekii, Shuhei
    Kasamatsu, Takahiro
    Kato, Shingo
    Hirowatari, Hisako
    Ikushima, Hitoshi
    Ando, Ken
    Ohno, Tatsuya
    Okamoto, Hiroyuki
    Okuma, Kae
    Igaki, Hiroshi
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [24] High precision radiotherapy including intensity - modulated radiation therapy and pulsed-dose-rate brachytherapy for cervical cancer: a retrospective monoinstitutional study
    Vavassori, Andrea
    Riva, Giulia
    Spoto, Ruggero
    Lazzari, Roberta
    Fodor, Cristiana
    Dicuonzo, Samantha
    Francia, Claudia Maria
    Augugliaro, Matteo
    Facondo, Giuseppe
    Cambria, Raffaella
    Comi, Stefania
    Cattani, Federica
    Botta, Francesca
    Bagnardi, Vincenzo
    Rizzo, Stefania
    Colombo, Nicoletta
    Orecchia, Roberto
    Jereczek-Fossa, Barbara Alicja
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2019, 11 (06) : 516 - 526
  • [25] Statistical Analysis of Interfraction Dose Variations of High-Risk Clinical Target Volume and Organs at Risk for Cervical Cancer High-Dose-Rate Brachytherapy
    Washington, Brien
    Randall, Marcus
    Fabian, Denise
    Cheek, Dennis
    Wang, Chi
    Luo, Wei
    ADVANCES IN RADIATION ONCOLOGY, 2022, 7 (06)
  • [26] Image-based 3D dosimetric studies with high dose rate intracavitary brachytherapy of cervical cancer
    Chakravarty, N.
    Semwal, M. K.
    Trivedi, G.
    Suhag, V
    Jain, M.
    Sharma, N.
    Vashisth, R. S.
    JOURNAL OF RADIOTHERAPY IN PRACTICE, 2020, 19 (03) : 277 - 280
  • [27] Novel use of ViewRay MRI guidance for high-dose-rate brachytherapy in the treatment of cervical cancer
    Ko, Huaising C.
    Huang, Jessie Y.
    Miller, Jessica R.
    Das, Rupak K.
    Wallace, Charles R.
    De Costa, Anna-Maria A.
    Francis, David M.
    Straub, Margaret R.
    Anderson, Bethany M.
    Bradley, Kristin A.
    BRACHYTHERAPY, 2018, 17 (04) : 680 - 688
  • [28] Evaluation of rectal volume correlation with dosimetric parameters during optimized intracavitary high-dose-rate brachytherapy in cervical cancer
    Shahbazian, Hodjatollah
    Birgani, Mohammad Javad Tahmasebi
    Bagheri, Ali
    Arvandi, Shole
    Razmjoo, Sasan
    Ghadamgahi, Pari
    Bakhali, Roksana
    Feli, Maryam
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2020, 12 (02) : 201 - 206
  • [29] Concomitant cervical and transperineal parametrial high-dose-rate brachytherapy boost for locally advanced cervical cancer
    Bailleux, Caroline
    Falk, Alexander Tuan
    Chand-Fouche, Marie-Eve
    Gautier, Mathieu
    Barranger, Emmanuel
    Hannoun-Levi, Jean-Michel
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2016, 8 (01) : 23 - 31
  • [30] Magnetic Resonance Imaging-Guided High-Dose Rate Brachytherapy for Cervical Cancer
    Meier, Teresa
    Kharofa, Jordan
    SEMINARS IN ROENTGENOLOGY, 2016, 51 (02) : 106 - 111